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A protective role for endothelial nitric oxide synthase in glo- cals such as peroxynitrite that initiate lipid peroxidation
merulonephritis. In acute glomerulonephritis (GN), increased and can damage proteins [2]. However, results from stud-
nitric oxide (NO) production occurs, suggesting a pathophysio- ies attempting to inhibit excessive NO production inlogical role for NO in the disease process. Although NO poten-
acute models of GN using competitive NO inhibitors aretially could have both toxic as well as protective effects, its exact
inconclusive and sometimes conflicting [1]. In many ofrole in the pathophysiology of GN is unclear and may depend
on the NOS isoform generating NO. The protective effects of these studies exacerbation of the disease occurred sug-
NO such as prevention of leukocyte and platelet activation and gesting that part of the NO response is protective. In
adhesion have been attributed to NO generated by endothelial general, these beneficial effects of NO have been attrib-nitric oxide synthase (eNOS). Evidence for a beneficial role
uted to the low levels of NO being generated by thefor eNOS includes the demonstration of reduced eNOS expres-
constitutive isoform of nitric oxide synthase (NOS) ex-sion in experimental models of GN as well as human biopsy
specimens that is mostly likely due to endothelial cell necrosis. pressed by the endothelium (eNOS).
Reduced NO production in GN also may occur through reac- Nitric oxide radicals generated by eNOS play an im-
tion of NO with superoxide anions or the myeloperoxidase portant role in the regulation of vascular homeostasis by(MPO)/hypochlorous acid (HOCL) system. Further evidence
inducing vasorelaxation and inhibiting platelet adhesionhas been provided by the observation that in several experi-
and aggregation to the endothelium [3–5]. In addition,mental models of GN, glomerular injury is exacerbated follow-
ing treatment with non-selective NO inhibitors. Finally, the several studies have demonstrated that eNOS derived
development of GN is severely aggravated in mice lacking NO is a critical modulator of leukocyte-endothelial cell
a functional gene for eNOS as compared to wild-type mice, interactions. Inhibition of NO production has been shownproviding direct support for a protective role of eNOS-derived
to promote leukocyte rolling and firm adherence in theNO in acute GN.
microcirculation and in several models of inflammation
NO donating agents or supplementation with l-arginine
has been found to reduce the extent of neutrophil-medi-It is well established now that acute glomerulonephri-
ated tissue injury [1, 6]. Here, we will discuss the evidencetis is associated with increased glomerular synthesis of
that eNOS-derived NO radicals exhibit properties thatnitric oxide (NO) [1]. In particular, this has been demon-
are beneficial in limiting inflammatory reactions in acutestrated in several well-defined animal models of glomeru-
glomerulonephritis.lonephritis such as nephrotoxic nephritis, active Heymann
nephritis and anti-Thy-1 nephritis. In these models, high
amounts of NO are generated by the inducible form of EXPRESSION OF eNOS
NOS expressed in infiltrating inflammatory cells such IN GLOMERULONEPHRITIS
as neutrophils and monocytes. These observations have
In the kidney, eNOS is constitutively expressed by
added NO to the list of mediators contributing to the
normal glomerular endothelium and interstitial vessels
development of tissue injury. Indeed, excessive amounts
[7]. Over the past few years, several studies have been
of NO can be directly cytostatic or cytotoxic by its reac-
reported regarding the expression of eNOS in GN em-
tion with iron sulfur groups and DNA. NO also may react
ploying experimental animal models of GN as well as
with superoxide anions generating highly reactive radi-
renal biopsies from patients with various forms of GN
[8–13]. The first report studying the status of eNOS in
experimental GN demonstrated a slight, biphasic, in-Key words: nitric oxide, endothelium, inflammation, kidney, renopro-
tection. crease in glomerular eNOS mRNA during the course of
anti-Thy-1 nephritis [8]. In rat as well as murine nephro- 2002 by the International Society of Nephrology
822
Heeringa et al: eNOS and glomerulonephritis 823
toxic nephritis models, a significant focal loss of glomeru- GN in the PVG/c rat, we have recently observed that
treatment with L-NAME exacerbated proteinuria andlar eNOS expression has been shown using immunogold
electron microscopy and immunohistochemistry, res- increased systolic blood pressure [18]. Compared to non-
treated rats, a marked increase in platelet aggregationpectively [12, 14]. Interestingly, the diminished eNOS
expression in the rat model was reversed by treatment was found whereas no differences in leukocyte accumula-
tion were observed.with a non-selective NO inhibitor [l-arginine methylester
(L-NAME)]. Using immunohistochemistry, the loss of In contrast to these detrimental consequences, bene-
ficial effects of NO inhibition in experimental GN haveeNOS expression also has been observed in an experi-
mental model of anti-myeloperoxidase (MPO) associ- also been reported. In the rat anti-Thy-1 model of GN,
Narita and colleagues have shown that infusion of aated GN induced by immunizing Brown Norway rats
with MPO followed by an unilateral perfusion of the left single dose of the l-arginine analog, L-NMMA, reduces
proteinuria and inhibits mesangiolysis to a large extentkidney with a neutrophil lysosomal extract containing
proteolytic enzymes, MPO and H2O2 [11]. In this model, [19]. In these studies, similar results were obtained using
a low protein diet or a diet depleted of l-arginine. Fur-immunohistochemical detection of platelets demon-
strated that, at sites where eNOS immunoreactivity was thermore, in spontaneous murine models of chronic au-
toimmune GN such as the MRL/lpr/lpr and New Zealandabsent, massive adhesion and aggregation of platelets
occurred, emphasizing the importance of eNOS-derived Black/White (NZB/W) mice, treatment with L-NMMA
has been shown to ameliorate proteinuria and the devel-NO in inhibiting platelet adhesion and aggregation. Al-
though other factors may be involved, the decrease of opment of proliferative GN [20, 21]. In contrast, how-
ever, no significant effect on GN was found when iNOSglomerular eNOS expression in this model is probably
due to endothelial cell necrosis, since at these sites immu- deficient mice were backcrossed to MRL/lpr/lpr mice,
although renal vasculitis and arthritis were reduced [22].nohistochemical staining for a rat endothelial cell marker
(RECA-1) was also absent. Based on the studies using pharmacological inhibition
of NO production described above, the exact role of NOStudies employing immunohistochemistry to investi-
gate eNOS expression in human renal biopsy specimens in the pathogenesis in GN remains unclear. In particular,
the use of l-arginine analogs that lack NOS isoformhave demonstrated a loss of glomerular eNOS expres-
sion in IgA nephropathy, lupus nephritis and Wegener’s specificity complicates interpretation of the results. Nev-
ertheless, these studies have provided indirect evidencegranulomatosis that was most prominent in areas of se-
vere glomerular injury [10, 13]. Moreover, an inverse that at least part of the NO response in GN, most likely
generated by eNOS, is protective.correlation between the extent of eNOS expression and
the degree of glomerular injury was found in IgA ne-
phropathy and lupus nephritis [10]. EFFECTS OF eNOS DEFICIENCY
Taken together, the above-mentioned studies indicate ON GLOMERULONEPHRITIS
that the development of glomerulonephritis is associated
Because most conventional NO inhibitors do not dis-with a reduction in overall eNOS expression that could
tinguish between the NOS isoforms, separate lines ofpotentially exacerbate the inflammatory response.
mice have been generated with targeted disruption of
the genes for inducible NOS (iNOS), neuronal NOS
EFFECTS OF PHARMACOLOGICAL (nNOS) as well as eNOS [23]. These gene-targeted mice
INHIBITION OF eNOS ACTIVITY have allowed the direct evaluation of NO generated by
ON GLOMERULONEPHRITIS one of the NOS isoforms in various physiological and
pathophysiological circumstances.Until recently, studies examining the effects of NO in
GN relied on the use of structural variants of l-arginine Mice lacking a functional gene for eNOS (eNOS /
mice) were originally generated to study the role ofthat compete with l-arginine for binding to the active
site of NOS. So far, results from these studies have been eNOS derived NO in blood pressure regulation [24, 25].
These studies showed that eNOS / mice are indistin-inconclusive and in some cases conflicting data exist. In
many of these studies, the use of l-arginine analogs such guishable from wild-type (WT) mice in general appear-
ance and histology, but have significantly increased bloodas L-NAME has been found to worsen disease. For
example, in rat nephrotoxic nephritis as well as in mod- pressures and an impaired vasorelaxation response to ace-
tylcholine. In addition, baseline and thrombin-inducedels of autoimmune Heymann nephritis treatment with
L-NAME exacerbated proteinuria [15–17]. Further- leukocyte rolling and adherence are significantly ele-
vated in the mesentery of eNOS / mice compared tomore, depletion of arginine levels through infusion of
arginase resulted in more glomerular thrombosis and WT mice that is associated with an increased surface
expression of P-selectin [26].aggravated glomerular disease in rat nephrotoxic nephri-
tis [15]. In the Thy-1 model of mesangioproliferative To specifically determine the role of eNOS derived
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NO in GN, we studied the course of murine accelerated However, other potential pathophysiological mecha-
nisms may be operative in GN that could affect eNOSanti-glomerular basement membrane (anti-GBM) in
eNOS / mice and C57BL/6j WT mice [12]. In this expression and activity.
In vitro studies have demonstrated that proinflamma-model, GN was induced by preimmunization with sheep
immunoglobulin G followed by intravenous administra- tory cytokines such as TNF- lower eNOS expression
in cultured endothelial cells [27]. Furthermore, eNOS-tion of a subnephritogenic dose of sheep anti-mouse
GBM antibody seven days later. In WT mice, GN devel- derived NO may react with other free radicals such as
superoxide leading to oxidative inactivation of NO [27].oped characterized by early (24 hours) glomerular neu-
trophil accumulation and glomerular thrombosis that Both TNF- and superoxide production have been docu-
mented in GN and could potentially alter bioactivity ofpersisted until day 10. In addition, at day 10 glomerular
hypercellularity and crescent formation in 17% of glo- NO [13, 28, 29].
More recently, an important role for myeloperoxidasemeruli were observed. In eNOS / mice, GN was se-
verely aggravated. In comparison to WT mice, increased (MPO) in modulating NO availability has been postu-
lated. The heme protein MPO is the most abundantmorbidity was observed and serum blood urea nitrogen
(BUN) levels were elevated indicating severe renal im- enzyme in neutrophils where it is contained in the azuro-
philic granules [30]. However, upon neutrophil activa-pairment in these mice. The most prominent feature of
the disease in eNOS/mice was extensive glomerular tion MPO can be readily released into phagocytic vacu-
oles as well as the extracellular space. MPO catalyzescapillary thrombosis often occluding all capillaries. At
day 10, a modest increase in glomerular neutrophil influx the oxidation of chloride by hydrogen peroxide resulting
in the formation of hypochlorous acid (HOCL) that canwas observed. Overall antibody depositions, glomerular
endocapillary hypercellularity and crescent formation, react with a variety of cellular substrates including thiols,
nucleotides and amines [30]. As such, MPO catalyzedhowever, were similar to that in WT mice.
To extend these observations, we recently studied the HOCL formation contributes to the microbial killing
function of neutrophils. However, when generated extra-effect of eNOS deficiency on heterologous nephrotoxic
nephritis induced by a single dose of rabbit anti-mouse cellularly it also may induce tissue injury.
The interaction between MPO and NO has recentlyGBM antibodies (E. Steenbergen, unpublished results).
Compared to WT mice, the glomerular neutrophil influx been investigated [31]. This study demonstrated that NO
can serve as a substrate for MPO in the presence ofwas markedly enhanced in eNOS/mice at two hours
[5.4  2.6 (N  7) vs. 2.4  1.6 (N  8), P  0.02 in H2O2, raising the possibility that MPO functions as a
catalytic sink for NO in vivo. Furthermore, Zhang andeNOS / and WT mice, respectively]. Also, at 3 days
after induction of the disease, elevated serum BUN levels colleagues have demonstrated that HOCL can react with
l-arginine to form novel chlorinated metabolites [31, 32].were detected whereas an increase in overall glomerular
capillary thrombosis was observed. Taken together, these Interestingly, these chlorinated l-arginine compounds
exhibited inhibitory effects on endothelium-dependentresults provide further evidence for a protective role for
eNOS-derived NO production in glomerulonephritis. vasorelaxation in vivo as well as in vitro, displaying simi-
lar pharmacological properties as conventional NOS in-
hibitors such as L-NAME. From these results the authorsFACTORS THAT MAY AFFECT eNOS
postulated that chlorinated l-arginine metabolites repre-EXPRESSION AND ACTIVITY
sent endogenous competitive inhibitors of eNOS. TheseIN GLOMERULONEPHRITIS
studies indicate that activation of the MPO/HOCL sys-
Although eNOS expression is constitutive, in vitro tem may limit the bioavailability of NO in vivo, an effect
studies have demonstrated that its expression can be that would be especially relevant at sites of inflammation
subject to modulation. Several factors have been identi- where MPO, NO and H2O2 are present. Whether these
fied that either increase (such as, shear stress) or decrease MPO related mechanisms play a role in GN remains to
[for example, hypoxia, endotoxin and tumor necrosis be determined. In this respect, it is interesting to note
factor- (TNF-)] eNOS expression [27]. Thus, patho- that catalytically active MPO has been detected in GN
physiological mechanisms may be operative in GN that in conjunction with the occurrence of HOCL-modified
alter glomerular eNOS expression either at the transcrip- proteins [28, 33].
tional or post-transcriptional level. As discussed before,
studies in experimental models of GN and human renal
CONCLUSIONSbiopsies indicate that the development of glomerulone-
phritis is associated with a decrease in overall glomerular This article summarizes the evidence supporting a pro-
tective role for eNOS-derived NO in the developmenteNOS expression. In most cases, this loss of eNOS pro-
tein expression appears to be secondary to severe glo- of GN. This evidence includes the demonstration of re-
duced endothelial NO production in GN that may occurmerular inflammation causing endothelial cell necrosis.
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glomerular basement membrane glomerulonephritis. Am J Patholdue to loss of eNOS expression caused by endothelial cell
156:879–888, 2000
necrosis or through the reaction of NO with superoxide 13. Heeringa P, Bijl M, de Jager-Krikken A, et al: Renal expression
of endothelial and inducible nitric oxide synthase, and formationanions or the MPO/HOCL system. In GN, eNOS-derived
of peroxynitrite-modified proteins and reactive oxygen species inNO production could be protective through its inhibitory
Wegener’s granulomatosis. J Pathol 193:224–232, 2001
effects on platelet aggregation and leukocyte adhesion. 14. Bremer V, Tojo A, Kimura K, et al: Role of nitric oxide in rat
nephrotoxic nephritis: Comparison between inducible and consti-The exacerbating effects of non-selective inhibition and
tutive nitric oxide synthase. J Am Soc Nephrol 8:1712–1721, 1997selective eNOS deficiency in experimental models of GN
15. Waddington S, Cook HT, Reaveley D, et al: L-arginine depletion
appear to confirm this contention. inhibits glomerular nitric oxide synthesis and exacerbates rat neph-
rotoxic nephritis. Kidney Int 49:1090–1096, 1996
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